Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. on July 17, 2013. The filing addresses the company's financial condition as of the end of the fiscal quarter on June 30, 2013, based on a preliminary prospectus supplement.
Key Financial Metrics
- Cash and Investments: The company expects to report $36.8 million in cash, cash equivalents, and investments as of June 30, 2013.
- Revenue, Profit, and Margins: The filing text does not provide clear values for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: Specific debt figures are not disclosed; however, the reported cash position indicates the company's liquidity status.
Material Changes
The filing does not provide comparative data for the prior period to determine material changes in financial performance. The primary disclosure is the expected cash balance at the end of the quarter.
Guidance, Outlook, and Risks
Management disclosed the expected cash position in a preliminary prospectus supplement. The filing explicitly states that full financial results for the quarter ended June 30, 2013, have not been finalized. No specific forward-looking guidance, risk factors, or unusual items are detailed in this specific report text.
Investor Verification Checklist
- Verify the finalized financial results for the quarter ended June 30, 2013, once officially released.
- Confirm the exact breakdown of the $36.8 million between cash, cash equivalents, and investments.
- Review the full preliminary prospectus supplement referenced in the filing for additional context on capital usage.